Immunocore announces 2026 strategic priorities

Immunocore (IMCR) set out its strategic priorities for 2026 including its plans for reaching more patients with melanoma and other diseases with high unmet needs. The Company highlights the potential of its melanoma franchise building on KIMMTRAK’s performance including the completion of enrollment in TEBE-AM, the registrational late-line cutaneous melanoma trial, in the first half of this year. In addition to enrolling patients in three Phase 3 trials, the Company expects to present data from multiple Phase 1/2 trials in 2026. “2026 will be an important year for Immunocore. We are building a leading melanoma franchise – first with KIMMTRAK, the standard of care for HLA-A*02:01-positive patients with metastatic uveal melanoma, and next in cutaneous melanoma through the TEBE-AM Phase 3 trial, which is our top priority for 2026,” said Bahija Jallal, CEO of Immunocore. “We expect to complete enrollment in the first half, positioning us for data readout as early as the second half of the year. We also continue to advance our broad pipeline, with pivotal readouts in oncology and infectious diseases, and dosing of the first patient in our first autoimmune trial this year.”